argenex (NASDAQ:ARGX) Releases Quarterly Earnings Results, Beats Estimates By $0.36 EPS

Posted by George Bondi on Oct 24th, 2026

argenex (NASDAQ:ARGX – Get Free Report) announced its earnings results on Friday. The company reported $7.80 EPS for the quarter, topping the consensus estimate of $7.44 by $0.36, Zacks reports. The business had revenue of $1.75 billion during the quarter. argenex had a net margin of 31.66% and a return on equity of 35.77%.

argenex Price Performance

ARGX stock traded down $2.05 during midday trading on Friday, reaching $873.71. 295,822 shares of the stock were exchanged, compared to its average volume of 509,396. The stock has a market capitalization of $54.94 billion, a PE ratio of 30.49, a P/E/G ratio of 0.79 and a beta of 0.44. The company has a fifty day moving average price of $956.62 and a 200 day moving average price of $885.37. argenex has a 52 week low of $661.85 and a 52 week high of $1,072.75.

More argenex News

Here are the key news stories impacting argenex this week:

Positive Sentiment: Strong quarterly results: argenx reported $7.80 in EPS, exceeding the $7.44 consensus estimate, while revenue reached $1.75 billion. Product net sales grew 54% year over year to $1.7 billion, and operating profit was $486 million. argenx Reports Third Quarter 2026 Financial Results and Provides Business Update
Positive Sentiment: Bullish analyst support: Morgan Stanley raised its price target from $1,140 to $1,190 and maintained an “overweight” rating. Wells Fargo also maintained “overweight” despite trimming its target from $1,356 to $1,336. Jefferies called the post-news setup a potentially attractive entry point. Morgan Stanley rating
Neutral Sentiment: Targets remain above the market price, but revisions are mixed: Guggenheim lowered its target from $1,185 to $1,120 while keeping a “buy” rating. Robert W. Baird raised its target from $823 to $861 but retained a “neutral” rating, and RBC reportedly cut its target. These changes suggest continued confidence in long-term value but more cautious near-term expectations. Guggenheim rating
Negative Sentiment: Clinical-development setback is overshadowing the earnings beat: Reports highlighted a surprise testing setback for argenx’s core drug, raising concerns about future growth, product expansion and execution. That issue appears to be driving the weaker investor reaction despite the company’s strong sales and profitability. argenx testing setback

Wall Street Analyst Weigh In

ARGX has been the topic of a number of recent research reports. Wells Fargo & Company lowered their target price on argenex from $1,356.00 to $1,336.00 and set an “overweight” rating on the stock in a research note on Friday. Truist Financial raised their price target on shares of argenex from $1,030.00 to $1,095.00 and gave the stock a “buy” rating in a research report on Tuesday, August 18th. Morgan Stanley boosted their price objective on shares of argenex from $1,140.00 to $1,190.00 and gave the company an “overweight” rating in a report on Friday. Deutsche Bank Aktiengesellschaft restated a “neutral” rating on shares of argenex in a research report on Friday, October 9th. Finally, Wedbush lowered their target price on shares of argenex from $1,150.00 to $1,130.00 and set an “outperform” rating on the stock in a report on Thursday, October 8th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat.com, argenex presently has a consensus rating of “Moderate Buy” and an average target price of $1,142.37.

Check Out Our Latest Report on argenex

argenex Company Profile

(Get Free Report)

argenx SE (NASDAQ: ARGX) is a global immunology company focused on developing and commercializing therapies for patients with severe autoimmune diseases. The company uses its antibody engineering capabilities to discover and advance medicines designed to target disease-causing immune mechanisms.

argenx’s lead product is VYVGART (efgartigimod alfa), an antibody fragment that targets the neonatal Fc receptor, or FcRn, to reduce levels of disease-causing immunoglobulin G antibodies. VYVGART is approved in several markets for the treatment of generalized myasthenia gravis.